Thrivent Financial for Lutherans Buys 110,481 Shares of Certara, Inc. (NASDAQ:CERT)

Thrivent Financial for Lutherans lifted its stake in Certara, Inc. (NASDAQ:CERT) by 128.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 196,391 shares of the company’s stock after acquiring an additional 110,481 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Certara were worth $2,091,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Wasatch Advisors LP boosted its holdings in Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after purchasing an additional 1,651,076 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Certara by 169.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock valued at $21,248,000 after buying an additional 1,253,385 shares during the period. Glenmede Trust Co. NA boosted its stake in shares of Certara by 78.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after buying an additional 530,598 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Certara in the fourth quarter worth $3,628,000. Finally, Edgestream Partners L.P. increased its position in Certara by 140.3% during the fourth quarter. Edgestream Partners L.P. now owns 365,708 shares of the company’s stock valued at $3,895,000 after acquiring an additional 213,549 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

CERT opened at $9.91 on Friday. The firm has a market cap of $1.60 billion, a P/E ratio of -49.55, a PEG ratio of 9.29 and a beta of 1.60. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.18. The company has a 50 day simple moving average of $12.43 and a two-hundred day simple moving average of $11.44. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. William Blair reissued a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Barclays raised their price objective on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Stephens reissued an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.